Why do some lung cancer patients respond to immunotherapy while others do not? Multimodal genomic features recently published in Nature Cancer may help identify patients that benefit most from immune checkpoint blockade.
📡 Some #Cancer #Immunotherapies ‼️ dissects multimodal genomic features to predict immune checkpoint blockade response, explaining the lack of power of individual feats such as PDL1 expression, HLA, or TMB alone. Check it out:
Study finds correlation of tumor mutation burden and tumor purity in whole-exome and targeted sequencing data, suggests new method to predict response to immune checkpoint blockade
Excited to see the inaugural issue of and our study Multimodal Genomic Features Predict Outcome To Immunotherapy go live! #UADResearchGroup
Multimodal genomic features predict outcome of immune checkpoint blockade in NSCLC: #LCSM #ImmunoOnc
#OncoAlert Multimodal genomic features suggested to predict outcome of immune checkpoint blockade in non-small-cell lung cancer | Nature Cancer #IO #immunotherapy
So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA —multi-omics & "tumor purity" by
Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer